Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.32 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.32 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.32 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.32 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.32 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10293135 | 0.93 | EDNRB (0.33) | EDNRBEDNRACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10292665 | 0.92 | EDNRA (0.36) | EDNRBEDNRACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10267986 | 0.91 | EDNRA (0.35) | EDNRBEDNRACYP3A4KDM4EALDH1A1 | |
| SCHEMBL16301289 | 0.89 | EDNRB (0.31) | EDNRBEDNRA | |
| SCHEMBL16301290 | 0.89 | EDNRB (0.31) | EDNRBEDNRA | |
| SCHEMBL10293033 | 0.88 | EDNRB (0.31) | EDNRBEDNRA | |
| SCHEMBL13868727 | 0.88 | EDNRB (0.31) | EDNRBEDNRA | |
| SCHEMBL16301285 | 0.88 | EDNRB (0.31) | EDNRBEDNRAALDH1A1 | |
| SCHEMBL16301312 | 0.88 | EDNRB (0.31) | EDNRBEDNRAALDH1A1 | |
| SCHEMBL11941326 | 0.88 | EDNRB (0.31) | EDNRBEDNRAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691120-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20120170098-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120170098-A1 | CHROMENE COMPOUND | CRY2, CRY1, SUN2 | EDNRB 3499/4885EDNRA 2966/4885CYP3A4 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.